<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-701" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fosinopril</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alessi</surname>
            <given-names>Kaitlyn</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kaitlyn Alessi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-701.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fosinopril belongs to the class of angiotensin-converting enzyme (ACE) inhibitors used in cardiovascular conditions for nearly 3 decades.&#x000a0;Fosinopril has received approval from the United States Food and Drug Administration (FDA) for the treatment of hypertension and heart failure.&#x000a0;Being a competitive inhibitor of ACE, fosinopril prevents the conversion of angiotensin I to angiotensin II&#x02014;a powerful vasoconstrictor.&#x000a0;Other ACE inhibitors approved in the United States include captopril, enalapril, lisinopril, benazepril, quinapril, ramipril, moexipril, fosinopril, and trandolapril.</p>
        <p>Fosinopril is utilized off-label for conditions such as acute myocardial infarction, diabetic nephropathy, and HIV-associated nephropathy. The drug is distinguishable from enalapril and captopril due to its long half-life, hydrophilicity, and resistance to liver breakdown. This activity reviews the mechanism of action, pharmacology, adverse event profiles, eligible patient populations, and monitoring of fosinopril,&#x000a0;highlighting the role of the interprofessional healthcare team in the management of hypertension with the drug.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between FDA-approved indications for fosinopril, specifically in hypertension and heart failure, and recognize its off-label uses in&#x000a0;acute myocardial infarction and diabetic nephropathy.</p></list-item><list-item><p>Implement fosinopril therapy according to evidence-based guidelines, incorporating dosage adjustments and monitoring for optimal effectiveness and safety.</p></list-item><list-item><p>Select fosinopril as an appropriate intervention in the management of hypertension, demonstrating a rationale based on patient-specific considerations.</p></list-item><list-item><p>Collaborate with the interprofessional healthcare team to ensure coordinated care in fosinopril therapy, particularly in patients with complex medical histories.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=701&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=701">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-701.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fosinopril belongs to the class of angiotensin-converting enzyme (ACE) inhibitors used in cardiovascular conditions for nearly 3 decades.&#x000a0;The drug is distinguishable from enalapril and captopril due to its long half-life, hydrophilicity, and resistance to liver breakdown.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Fosinopril has received approval from the United States Food and Drug Administration (FDA) for the treatment of hypertension and heart failure. Other ACE inhibitors approved in the United States include captopril, enalapril, lisinopril, benazepril, quinapril, ramipril, moexipril, fosinopril, and trandolapril.<xref ref-type="bibr" rid="article-701.r1">[1]</xref>&#x000a0;Fosinopril is most often prescribed for patients suffering from hypertension (&#x0003c;140/90 mm Hg for non-complicated patients and &#x0003c;130/80 mm Hg for patients with either diabetes or chronic kidney disease).<xref ref-type="bibr" rid="article-701.r2">[2]</xref></p>
        <p>Being a competitive inhibitor of ACE, fosinopril&#x000a0;prevents&#x000a0;the conversion of angiotensin I to angiotensin II&#x02014;a powerful vasoconstrictor. According to the guidelines published by the American Heart Association, American College of Cardiology and Heart Failure Society of America (AHA/ACC/HFSA) in 2022, ACE inhibitors, like&#x000a0;fosinopril are&#x000a0;indicated in guideline-directed medical therapy (GDMT) for the treatment of&#x000a0;HFrEF (heart failure with reduced ejection fraction) along with conventional therapy that includes diuretics with or without digitalis. Once-daily fosinopril has been shown to improve&#x000a0;heart failure (HF)&#x000a0;signs and symptoms and reduce hospitalizations for worsening HF.<xref ref-type="bibr" rid="article-701.r3">[3]</xref>&#x000a0;In a fosinopril efficacy/safety trial (FEST), fosinopril improved exercise tolerance and attenuated&#x000a0;clinical deterioration in patients with heart failure.<xref ref-type="bibr" rid="article-701.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Fosinopril is utilized off-label for conditions such as acute myocardial infarction, diabetic nephropathy, and HIV-associated nephropathy. A fosinopril acute myocardial infarction study (FAMIS) demonstrated that early treatment with fosinopril benefits patients with acute myocardial infarction and prevents left ventricular (LV) remodeling.<xref ref-type="bibr" rid="article-701.r5">[5]</xref></p>
        <p>Fosinopril is also a preventative therapy for patients with diabetic nephropathy. In a randomized clinical trial of patients with diabetic nephropathy, fosinopril combined treatment with losartan resulted in reduced 24-hour total urine protein excretion, serum creatinine, and BUN.<xref ref-type="bibr" rid="article-701.r6">[6]</xref>&#x000a0;Fosinopril&#x000a0;is also efficacious for treating HIV-associated nephropathy (HIVAN).<xref ref-type="bibr" rid="article-701.r7">[7]</xref></p>
      </sec>
      <sec id="article-701.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fosinopril is an ester prodrug that hydrolyzes in the liver to fosinoprilat, the active metabolite form. Fosinoprilat competitively&#x000a0;binds to ACE, resulting in decreased formation of angiotensin II, reduced aldosterone concentrations, and diminished systemic vasoconstriction. Fosinopril can reduce vasoconstriction and promote sodium excretion by interacting with renin-angiotensin-aldosterone system (RAAS) components. It helps in heart failure by protecting the myocardium from the angiotensin II remodeling effects.<xref ref-type="bibr" rid="article-701.r8">[8]</xref><xref ref-type="bibr" rid="article-701.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Peak concentration is attained in approximately 3 hours.&#x000a0;The site&#x000a0;of absorption of fosinopril is the duodenum and jejunum.<xref ref-type="bibr" rid="article-701.r10">[10]</xref>&#x000a0;</p>
        <p><bold>Distribution:</bold> Fosinoprilat&#x000a0;has&#x000a0;a high plasma protein binding (PPB&#x0003e; 99%). Fosinopril can cross the blood-brain barrier.<xref ref-type="bibr" rid="article-701.r11">[11]</xref></p>
        <p><bold>Metabolism:</bold> Fosinopril is metabolized in the liver by carboxylesterases to fosinoprilat.<xref ref-type="bibr" rid="article-701.r12">[12]</xref></p>
        <p><bold>Elimination:</bold> Fosinopril and its metabolite&#x000a0;fosinoprilat&#x000a0;are eliminated&#x000a0;by&#x000a0;the liver and kidney.<xref ref-type="bibr" rid="article-701.r13">[13]</xref></p>
      </sec>
      <sec id="article-701.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Fosinopril received official approval in 1991 and is available for administration&#x000a0;in 10 mg, 20 mg, or 40 mg oral tablets. The drug is typically prescribed at a low dose, and the dosage is increased as needed while evaluating the patient&#x02019;s response and tolerance. The maximum dose is typically 80 mg for the average patient with hypertension.&#x000a0;In patients with&#x000a0;sodium&#x000a0;or water depletion or renal failure, the initial dosing is reduced to 5 mg. Co-administer hydrochlorothiazide with fosinopril to regulate fluid volume and counteract high blood pressure.<xref ref-type="bibr" rid="article-701.r14">[14]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Monotherapy: The recommended initial adult dose of fosinopril is 10 mg once daily, both as monotherapy and when the drug is added to diuretic treatment. The dose can be adjusted according to the patient&#x02019;s blood pressure at peak (in 2 to 6 hours) and trough (at 24 hours) blood levels. Most patients gain optimum blood pressure control with 20 to 40 mg daily; only a few&#x000a0;require an 80 mg dose. However, if the blood pressure control response is inadequate around the end of the dosing interval, dividing the daily dose may give better control.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Coadministration with diuretics:&#x000a0;A diuretic can be added if blood pressure is inadequately controlled with fosinopril. Coadministration of fosinopril with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics can increase serum potassium.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients treated with a diuretic, symptomatic hypotension can result following the initial dose of fosinopril. To reduce the chances of hypotension, the diuretic should, if possible, be discontinued&#x000a0;2 to&#x000a0;3 days before beginning therapy with fosinopril. Then, if blood pressure is not adequately controlled, the diuretic should be resumed. If diuretic treatment cannot be stopped, start fosinopril at 10 mg with close medical supervision for several hours until the patient&#x02019;s blood pressure is stabilized.</p>
          </list-item>
        </list>
        <p><bold>Heart failure:&#x000a0;</bold>According to AHA/ACC/HFSA guidelines, fosinopril is indicated for HFrEF. Fosinopril should be initiated at 5 to 10 mg once daily; the target dose is 40 mg daily.<xref ref-type="bibr" rid="article-701.r15">[15]</xref>&#x000a0;Observe patients under medical supervision for at least 2 hours for any hypotension and/or orthostasis.&#x000a0;A starting dose of 5 mg is recommended in patients with heart failure and moderate to severe renal failure. Then, the dose should be increased over several weeks but not more than 40 mg daily. The usual effective dose range is 20 mg to 40 mg&#x000a0;daily.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>In patients with renal impairment, the total clearance of fosinoprilat slows by 50%. However, hepatobiliary elimination partially compensates for diminished renal elimination. Hence, the total body clearance of fosinoprilat remains normal with all degrees of renal impairments (CrCl &#x0003c; 80 mL/min/1.73 m&#x000b2;), including end-stage renal diseases.</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Use with caution in patients with hepatic impairment. According to The American Association for the Study of Liver Diseases (AASLD), ACE inhibitors should not be&#x000a0;administered in patients with cirrhosis and ascites.<xref ref-type="bibr" rid="article-701.r16">[16]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Fosinopril is contraindicated during pregnancy due to&#x000a0;the ability to cross the placenta. As a result,&#x000a0;the drug may increase the risk of fetal malformations and cause congenital disabilities or death to the developing fetus.&#x000a0;The medication&#x000a0;should stop immediately if the patient reports pregnancy at any time during treatment. All ACE inhibitors should be avoided when treating hypertension in pregnancy.<xref ref-type="bibr" rid="article-701.r17">[17]</xref><xref ref-type="bibr" rid="article-701.r18">[18]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>The manufacturer recommends against breastfeeding using fosinopril as it is secreted in breast milk.<xref ref-type="bibr" rid="article-701.r19">[19]</xref></p>
        <p><bold>Older patients: </bold>The dose is similar to the adult dose; however, clinicians should consider&#x000a0;impaired renal function and the risk of polypharmacy.<xref ref-type="bibr" rid="article-701.r20">[20]</xref></p>
        <p><bold>Pediatric patients: </bold>According to the American Academy of Pediatrics (AAP) guidelines for hypertension, the recommended starting dose of fosinopril for age group&#x000a0;&#x0003e;6 years and weight &#x0003c;50 kg is 0.1 mg/kg daily (up to 5 mg per day), and the maximum recommended&#x000a0;dose is 40 mg daily. If weight is &#x0003e;50 kg, the initial dose is 5 mg, and the maximum recommended dose is 40 mg.<xref ref-type="bibr" rid="article-701.r21">[21]</xref></p>
      </sec>
      <sec id="article-701.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common symptoms reported with fosinopril include fatigue, dizziness, gastrointestinal disturbances, dry cough, and a skin rash.<xref ref-type="bibr" rid="article-701.r14">[14]</xref></p>
        <p>Long-term usage of fosinopril can produce a dry cough due to ACE inhibition and the resulting accumulation of bradykinin. A less common&#x000a0;but potentially life-threatening complication is&#x000a0;angioedema.&#x000a0;Intestinal angioedema is reported&#x000a0;with fosinopril. In such instances, discontinuation of fosinopril is advised.<xref ref-type="bibr" rid="article-701.r22">[22]</xref></p>
        <p>Other rarely reported adverse reactions are elevated serum aminotransferase concentrations and acute liver damage. Less than&#x000a0;2%&#x000a0;of patients using fosinopril have reported increased serum aminotransferase levels without explanation.&#x000a0;Since acute liver damage is an infrequent reaction, only a handful of clinical reports have been documented and analyzed. Unfortunately, these few reports are insufficient to determine a consistent mechanism of injury, so the path of liver damage remains unknown in these patients.&#x000a0;A metabolite reaction in the liver is proposed to cause the adverse effect.<xref ref-type="bibr" rid="article-701.r14">[14]</xref>&#x000a0;Other ACE inhibitors demonstrating&#x000a0;similar liver damage are enalapril and lisinopril.<xref ref-type="bibr" rid="article-701.r1">[1]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Potassium (K+) sparing diuretics: Fosinopril may cause hyperkalemia due to the attenuation of potassium loss caused by potassium-sparing diuretics.<xref ref-type="bibr" rid="article-701.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lithium: Fosinopril causes serious drug interaction with lithium; it may slow the elimination of lithium from the body, resulting in increased lithium levels.<xref ref-type="bibr" rid="article-701.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Antacids: Antacids may alter the absorption of fosinopril, resulting in reduced serum levels. Fosinopril can further reduce the urinary excretion of fosinoprilat.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nonsteroidal&#x000a0;anti-inflammatory agents: In elderly patients, co-administration of fosinopril may result in deterioration of renal function, resulting in acute renal failure.<xref ref-type="bibr" rid="article-701.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>mTOR inhibitors: Concomitant&#x000a0;administration of mTOR inhibitors like temsirolimus increases the risk for angioedema.<xref ref-type="bibr" rid="article-701.r26">[26]</xref><xref ref-type="bibr" rid="article-701.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-701.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>The incidence of angioedema occurring as an adverse effect is 0.1% to 0.7% due to vasodilation and plasma extravasation.<xref ref-type="bibr" rid="article-701.r28">[28]</xref>&#x000a0;Patients with a past medical history of ACE inhibitor-induced angioedema should avoid using fosinopril or any other agent within that class.<xref ref-type="bibr" rid="article-701.r29">[29]</xref><xref ref-type="bibr" rid="article-701.r30">[30]</xref></p>
        <p>In cases of hepatic failure,&#x000a0;clinicians must avoid prescribing any ACE inhibitors. In addition, patients experiencing the adverse effects of acute liver injury from fosinopril should refrain from using other ACE inhibitors to prevent further damage.<xref ref-type="bibr" rid="article-701.r14">[14]</xref>&#x000a0;In patients with diabetes, fosinopril should not be co-administered with aliskiren, as aliskiren may enhance fosinopril's hypotensive, hyperkalemic, and nephrotoxic effects.<xref ref-type="bibr" rid="article-701.r31">[31]</xref></p>
      </sec>
      <sec id="article-701.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When&#x000a0;on fosinopril therapy, the patient requires monitoring for hypotension, potassium levels, renal function, and angioedema. To decrease the possibility of hypotension as an adverse effect among ACE inhibitors, the recommendation is to prescribe fosinopril at a low dose initially. During weeks 2&#x000a0;to 3 of usage, clinicians should note serum creatine, potassium levels, and blood pressure to estimate the patient's tolerance. For instance, a patient with a history of hyperkalemia or a high-potassium diet should be closely monitored to avoid exacerbating any preexisting conditions.<xref ref-type="bibr" rid="article-701.r32">[32]</xref></p>
        <p>ACE inhibitors, especially captopril, are associated with agranulocytosis in patients with collagen-vascular disease&#x000a0;and concurrent&#x000a0;renal impairment. Sufficient clinical data are not available to rule out fosinopril-associated agranulocytosis; consequently, monitoring CBC with a differential&#x000a0;in patients with collagen vascular diseases is considered.<xref ref-type="bibr" rid="article-701.r33">[33]</xref></p>
      </sec>
      <sec id="article-701.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>If the patient is experiencing fosinopril toxicity, they require supportive care and should discontinue fosinopril immediately. Angioedema requires discontinuation of fosinopril, treatment with epinephrine, and endotracheal intubation&#x000a0;for airway compromise.<xref ref-type="bibr" rid="article-701.r28">[28]</xref>&#x000a0;</p>
        <p>The&#x000a0;first case study that documented uncommon adverse reactions due to fosinopril showed interactions with metoprolol and diazepam. Signs of asthenia, jaundice, and pruritus were present. When fosinopril&#x000a0;was&#x000a0;discontinued, and pruritus and cholestasis were treated,&#x000a0;the signs of severe toxicity&#x000a0;continued. Recovery lasted up to 18 months.&#x000a0;The risk of developing acute liver injury due to fosinopril was categorized as a likelihood score of D. Other ACE inhibitors have shown similar risks for acute liver damage leading to a long period of hospitalization and recovery.</p>
        <p>As such, ursodiol, colestipol, and hydroxyzine are recommended for signs of liver damage, but the immediate cessation of fosinopril is one of the first steps in managing toxicity.</p>
      </sec>
      <sec id="article-701.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Fosinopril is a relatively safe and common medication used&#x000a0;to treat hypertension and heart failure, but monitoring the treatment and reporting any adverse reaction is essential. Prescribing clinicians initiate fosinopril for hypertension and heart failure. A cardiologist consultation is vital for complicated HFrEF and acute decompensated heart failure.</p>
        <p>Patient education is critical; interprofessional healthcare team members&#x000a0;should educate patients about possible&#x000a0;adverse effects and receive instructions to avoid high-potassium diets. To ensure the patient is maximizing benefits from fosinopril, clinicians should schedule regular follow-ups to document any adverse effects and adjust the regimen accordingly.</p>
        <p>At the outset of therapy, a pharmacist should verify appropriate dosing, check for potential interactions, and counsel&#x000a0;the patient on possible adverse effects. Nurses follow up with the patient, monitor therapy progress, and answer patient questions, alerting the prescriber to any concerns with recommended changes in therapy when indicated. Critical care consultation is required for overdose. Hepatologists or gastroenterologists can provide valuable inputs to prevent and manage drug-induced liver injury (DILI).<xref ref-type="bibr" rid="article-701.r34">[34]</xref>&#x000a0;</p>
        <p>For complicated fosinopril&#x000a0;overdose, a medical toxicologist should be consulted. Interprofessional strategies and open communication between prescribers, including specialists, pharmacists, and nurses, can optimize patient outcomes related to fosinopril therapy with fewer adverse effects.&#x000a0;</p>
      </sec>
      <sec id="article-701.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=701&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=701">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/701/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=701">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-701.s11">
        <title>References</title>
        <ref id="article-701.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Angiotensin-Converting Enzyme Inhibitors</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31644219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elliott</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Systemic hypertension.</article-title>
            <source>Curr Probl Cardiol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <page-range>201-59</page-range>
            <pub-id pub-id-type="pmid">17398315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shettigar</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hare</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gelperin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ilgenfritz</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Deitchman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of fosinopril on exercise tolerance, symptoms, and clinical outcomes in patients with decompensated heart failure.</article-title>
            <source>Congest Heart Fail</source>
            <year>1999</year>
            <season>Jan-Feb</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-34</page-range>
            <pub-id pub-id-type="pmid">12189330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erhardt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>MacLean</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ilgenfritz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gelperin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group.</article-title>
            <source>Eur Heart J</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1892</fpage>
            <page-range>1892-9</page-range>
            <pub-id pub-id-type="pmid">8682023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zardini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Magnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Collatina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ambrosioni</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party.</article-title>
            <source>Am Heart J</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>136</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-25</page-range>
            <pub-id pub-id-type="pmid">9704681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>QZ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Combination therapy with losartan and fosinopril for early diabetic nephropathy].</article-title>
            <source>Di Yi Jun Yi Da Xue Xue Bao</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>963</fpage>
            <page-range>963-5</page-range>
            <pub-id pub-id-type="pmid">13129736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Visintainer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sivak</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition.</article-title>
            <source>Kidney Int</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>1462</fpage>
            <page-range>1462-71</page-range>
            <pub-id pub-id-type="pmid">12969167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Omura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice.</article-title>
            <source>Heart</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>91</volume>
            <issue>8</issue>
            <fpage>1080</fpage>
            <page-range>1080-5</page-range>
            <pub-id pub-id-type="pmid">16020603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000fc;sing</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering.</article-title>
            <source>Ther Adv Cardiovasc Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>151</fpage>
            <page-range>151-61</page-range>
            <pub-id pub-id-type="pmid">27122491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2002</year>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-24</page-range>
            <pub-id pub-id-type="pmid">11929321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manly</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hudak</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hasebe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Nation</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis.</article-title>
            <source>Hypertension</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>629</fpage>
            <page-range>629-643</page-range>
            <pub-id pub-id-type="pmid">34148364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zisaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miskovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hatzimanikatis</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.</article-title>
            <source>Curr Pharm Des</source>
            <year>2015</year>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>806</fpage>
            <page-range>806-22</page-range>
            <pub-id pub-id-type="pmid">25341854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenbaum</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zucchelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Caspi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nouriel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Paz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sclarovsky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Grady</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Mangold</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-31</page-range>
            <pub-id pub-id-type="pmid">10606834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Fosinopril</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31644120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biggins</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Angeli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gin&#x000e8;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Nadim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>1014</fpage>
            <page-range>1014-1048</page-range>
            <pub-id pub-id-type="pmid">33942342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buawangpong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Teekachunhatean</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koonrungsesomboon</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e00644</fpage>
            <pub-id pub-id-type="pmid">32815286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Fosinopril</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">29999858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ju&#x000e1;rez-Cedillo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Martinez-Hern&#x000e1;ndez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Constantino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia-Cruz</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Avalos-Mejia</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Hurtado</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Islas Perez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hansten</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-305</page-range>
            <pub-id pub-id-type="pmid">26432499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kaelber</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Baker-Smith</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blowey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Dionne</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Falkner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leu</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simasek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thaker</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Urbina</surname>
                <given-names>EM</given-names>
              </name>
              <collab>SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN</collab>
            </person-group>
            <article-title>Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28827377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oudit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Girgrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management.</article-title>
            <source>Can J Gastroenterol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>827</fpage>
            <page-range>827-32</page-range>
            <pub-id pub-id-type="pmid">11773949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben Salem</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Badreddine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fathallah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Slim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hmouda</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced hyperkalemia.</article-title>
            <source>Drug Saf</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>677</fpage>
            <page-range>677-92</page-range>
            <pub-id pub-id-type="pmid">25047526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masom</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Lithium Toxicity from the Addition of an ACE Inhibitor with an Unexpected Type I Brugada Pattern ECG: Case Files of the Medical Toxicology Fellowship at the University of California, San Diego.</article-title>
            <source>J Med Toxicol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-328</page-range>
            <pub-id pub-id-type="pmid">32297151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charchar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wainford</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schutte</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1334</fpage>
            <page-range>1334-1357</page-range>
            <pub-id pub-id-type="pmid">32370572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duerr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glander</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Diekmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dragun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Neumayer</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>703</fpage>
            <page-range>703-8</page-range>
            <pub-id pub-id-type="pmid">20093343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charmillon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deibener</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaminsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibant.</article-title>
            <source>Intensive Care Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>893</fpage>
            <page-range>893-4</page-range>
            <pub-id pub-id-type="pmid">24737261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostis</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>ACE Inhibitor-Induced Angioedema: a Review.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2018</year>
            <month>Jun</month>
            <day>08</day>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">29884969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibbs</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Beevers</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Angioedema due to ACE inhibitors: increased risk in patients of African origin.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>861</fpage>
            <page-range>861-5</page-range>
            <pub-id pub-id-type="pmid">10594491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Snowden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-13</page-range>
            <pub-id pub-id-type="pmid">8689816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parving</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Persson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nicolaides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Brunel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <collab>ALTITUDE Investigators</collab>
            </person-group>
            <article-title>Cardiorenal end points in a trial of aliskiren for type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Dec</month>
            <day>06</day>
            <volume>367</volume>
            <issue>23</issue>
            <fpage>2204</fpage>
            <page-range>2204-13</page-range>
            <pub-id pub-id-type="pmid">23121378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andr&#x000e8;s</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Villalba</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Zulfiqar</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Serraj</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mourot-Cottet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gottenberg</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Sep</month>
            <day>01</day>
            <volume>8</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31480527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-701.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chalasani</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Maddur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>KR</given-names>
              </name>
              <collab>Practice Parameters Committee of the American College of Gastroenterology</collab>
            </person-group>
            <article-title>ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>116</volume>
            <issue>5</issue>
            <fpage>878</fpage>
            <page-range>878-898</page-range>
            <pub-id pub-id-type="pmid">33929376</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
